Ascendis Pharma Reports Third Quarter 2024 Financial Results
YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 - TransCon CNP NDA submission for achondroplasia planned for Q1 2025 ...
Meditation, deep breathing, yoga: Protect your heart from the dangers of chronic stress
Stress is a part of your everyday life. While a little stress here and there may be manageable, chronic stress can be far ...